Effect of non-steroidal anti-inflammatory drug etoricoxib on the hematological parameters and enzymes of colon and kidney.

The present study was designed to investigate the effects of a selective COX-2 inhibitor, etoricoxib in rats on the hematological and toxicity parameters in colon and kidney at two different doses of the drug, one within the therapeutic anti-inflammatory range as based on the reported ED50 value (Eto-1) while the other at ten times higher (Eto-2), relative to the toxicity studies which have not been reported so far. The results showed that the control and the drug treated animals achieved similar linear growth rate and also showed no major alterations in the histological parameters in the liver and kidney tissue. The animals treated with lower dose of etoricoxib showed an overall decrease in total leukocytes counts as well as in the number of neutrophils, lymphocytes, monocytes and eosinophills while the higher dose of the drug produced a highly significant increase in all the cell counts. However, the drug treatment at both the dose level produced significant fall in the activities of alkaline phosphatase, sucrase, lactase and maltase in the kidney but increased the activity of alkaline phosphatase in colon. The treatment of etoricoxib did not produce any change in the nitric oxide and citrulline levels in kidney while an increase was noted in the colonic tissue. It was concluded that etoricoxib is a relatively safe drug at its anti-inflammatory ED50 dose in rats when the hematological parameters and the structural and functional characteristics of kidney and colonic tissues were studied.

Effect of non-steroidal anti-inflammatory drug etoricoxib on the hematological parameters and enzymes of colon and kidney / Efecto del fármaco antiinflamatorio no esteroideo etoricoxib sobre los parámetros hematológicos y las enzimas del colon y el riñón

The present study was designed to investigate the effects of a selective COX-2 inhibitor, etoricoxib in rats on the hematological and toxicity parameters in colon and kidney at two different doses of the drug, one within the therapeutic anti-inflammatory range as based on the reported ED50 value (Eto-1) while the other at ten times higher (Eto-2), relative to the toxicity studies which have not been reported so far. The results showed that the control and the drug treated animals achieved similar linear growth rate and also showed no major alterations in the histological parameters in the liver and kidney tissue. The animals treated with lower dose of etoricoxib showed an overall decrease in total leukocytes counts as well as in the number of neutrophils, lymphocytes, monocytes and eosinophills while the higher dose of the drug produced a highly significant increase in all the cell counts. However, the drug treatment at both the dose level produced significant fall in the activities of alkaline phosphatase, sucrase, lactase and maltase in the kidney but increased the activity of alkaline phosphatase in colon. The treatment of etoricoxib did not produce any change in the nitric oxide and citrulline levels in kidney while an increase was noted in the colonic tissue. It was concluded that etoricoxib is a relatively safe drug at its anti-inflammatory ED50 dose in rats when the hematological parameters and the structural and functional characteristics of kidney and colonic tissues were studied (AU)

El presente estudio se diseñó para investigar los efectos de un inhibidor selectivo de la COX-2, etoricoxib, sobre los parámetros hematológicos y de toxicidad en colon y riñón de rata, con dos dosis distintas del fármaco, una dentro del rango terapéutico sobre la base del valor ED50 notificado (Eto-1) mientras que la otra fue diez veces superior (Eto-2), relativa a los estudios de toxicidad que aún no han sido publicados. Los resultados mostraron que los animales control y los tratados consiguieron tasas de crecimiento linear similares y no mostraron alteraciones importantes en los parámetros histológicos del hígado o riñón. Los animales tratados con la dosis inferior de etoricoxib mostraron una disminución global del recuento de neutrófilos, linfocitos, monocitos y eosinófilos, mientras que la dosis superior del fármaco produjo un aumento significativo de todos los recuentos celulares. Sin embargo, el tratamiento con el fármaco a ambas dosis produjo una caída significativa de las actividades de la fosfatasa alcalina, sucrasa, lactasa y maltasa del riñón y una actividad aumentada de la fosfatasa alcalina del colon. El tratamiento con etoricoxib no produjo ningún cambio en las concentraciones de óxido nítrico ni de citrulina en el riñón pero sí se observó un aumento en el tejido colónico. Se concluyó que el etoricoxib es un fármaco relativamente seguro a su dosis ED50 antiinflamatoria en ratas cuando se estudiaron los parámetros hematológicos y las características estructurales y funcionales de los tejidos renal y colónico (AU)